Economic aspects of vaccines and vaccination: a global perspective

  • Philippe P.A. Beutels
Part of the Birkhäuser Advances in Infectious Diseases BAID book series (BAID)


Gross Domestic Product Economic Evaluation Discount Rate Global Perspective Health Gain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    World Bank (2004) World Development Indicators, online publication available on CD ROM and at product?item_id=631625Google Scholar
  2. 2.
    WHO (2001) Commission on Macroeconomics and Health: investing in health for economic development. Available at CMHReport.pdfGoogle Scholar
  3. 3.
    Razzell PE (1977) The conquest of smallpox. Caliban Books, Firle (UK)Google Scholar
  4. 4.
    McKeown T, Record RG, Brown RG (1972) An interpretation of the modern rise of population in Europe. Population Studies 26: 345–382PubMedGoogle Scholar
  5. 5.
    Beutels P (2002) Economic evaluation of vaccination programmes in humans: a methodological exploration with applications to hepatitis B, varicella-zoster, measles, pertussis, hepatitis A and pneumococcal vaccination. University of Antwerp, AntwerpGoogle Scholar
  6. 6.
    Philipson T (2000) Economic epidemiology and infectious disease. In: Newhouse J, Culyer T (eds): Handbook of health economics. North-Holland, New York, 1761–1797Google Scholar
  7. 7.
    Anderson RM, May RM (1991) Infectious diseases of humans — dynamics and control. Oxford University Press, OxfordGoogle Scholar
  8. 8.
    Panagiotopoulos T, Antoniadou I, Valassi-Adam E (1999) Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. Brit Med J 319(7223): 1462–1467PubMedGoogle Scholar
  9. 9.
    Barrett S (2004) Economics of eradication vs control of infectious diseases. Bull WHO 82(9): 639–718Google Scholar
  10. 10.
    Kaddar M (2004) Lecture at the advanced course in vaccinology, International Vaccine Institute, Seoul, 2004. Data based on Frost & Sullivan, Datamonitor, Theta reports and GenesisGoogle Scholar
  11. 11.
    Smith RD, Sommers T (2003) Assessing the economic impact of communicable disease outbreaks: the case of SARS. Working paper WHO, July 2003Google Scholar
  12. 12.
    Lee JW, McKibbin W (2004) Globalization and Disease: The Case of SARS. Asian Economic Papers 3(1); in press Google Scholar
  13. 13.
    Drummond M, O’Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care programmes (second ed.). Oxford University Press, OxfordGoogle Scholar
  14. 14.
    Edmunds WJ, Dejene A, Mekonnen Y, Haile M, Alemnu W, Nokes DJ (2000) The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy and Planning 15(4): 408–416PubMedCrossRefGoogle Scholar
  15. 15.
    Hall AJ, Robertson RL, Crivelli PE, Lowe Y, Inskip H, Snow SK, Whittle H (1993) Cost-effectiveness of hepatitis B vaccine in The Gambia. Trans Roy Soc Trop Med Hyg 87: 333–336PubMedGoogle Scholar
  16. 16.
    Drummond M (1991) Output measurement for resource allocation decisions in health care. In: McGuire A, Fenn P, Mayhew K (eds): Providing health care. The economics of alternative systems of finance and delivery. University Press, Oxford, 99–119Google Scholar
  17. 17.
    Beutels P, Van Doorslaer E, Van Damme P, Hall J (2003) Methodological issues and new developments in the economic evaluation of vaccines. Exp Rev Vacc 2(5): 89–100Google Scholar
  18. 18.
    Mooney G (1992) The economics of health and medicine. Wheatsheaf, BrightonGoogle Scholar
  19. 19.
    Luce BR, Manning WG, Siegel JE, Lipscomb J (1996) Estimating costs in costeffectiveness analysis. In: Gold MR, Siegel JE, Russel LB, Weinstein MC (eds): Cost-effectiveness in health and medicine. Oxford University Press, New York, 176–213Google Scholar
  20. 20.
    Mishan EJ (1971) Evaluation of life and limb: a theoretical approach. Journal of Political Economy 79: 687–706Google Scholar
  21. 21.
    Olsen JA, Smith RD (2001) Theory versus practice: a review of “willingness to pay” in health and health care. Health Econ 10: 39–52PubMedCrossRefGoogle Scholar
  22. 22.
    Keeler J, Cretin S (1983) Discounting of life saving and other non-monetary effects. Management Science 29(3): 300–306CrossRefGoogle Scholar
  23. 23.
    Weinstein MC, Stason WB (1977) Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296: 716–721PubMedCrossRefGoogle Scholar
  24. 24.
    van Hout BA (1998) Discounting costs and effects: a reconsideration. Health Econ 7(7): 581–594PubMedGoogle Scholar
  25. 25.
    Gravelle H, Smith D (2001) Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 10(7): 587–599PubMedCrossRefGoogle Scholar
  26. 26.
    Devlin N, Parkin D (2004) Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13(5): 437–452PubMedGoogle Scholar
  27. 27.
    George B, Harris A, Mitchell A (2001) Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19(11): 1103–1109PubMedGoogle Scholar
  28. 28.
    Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ (2000) A comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studies. Med Decis Making 20(4): 451–467PubMedGoogle Scholar
  29. 29.
    Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD (1995) Fivehundred life-saving interventions and their cost-effectiveness. Risk Anal 15(3): 369–390PubMedGoogle Scholar
  30. 30.
    Shearley AE (1999) The societal value of vaccination in developing countries. Vaccine 17(Suppl 3): S109–S112PubMedGoogle Scholar
  31. 31.
    Bishai D, Koenig M, Ali Khan M (2003) Measles vaccination improves the equity of health outcomes: evidence from Bangladesh. Health Econ 12(5): 415–419PubMedGoogle Scholar
  32. 32.
    UNICEF (2001) The State of the World’s Children. Early childhood. Available at Scholar
  33. 33.
    Global Forum for Health Research (2004) The 10/90 gap report 2004. Available at Scholar
  34. 34.
    Kaddar M, Lydon P, Levine R (2004) Financial challenges of immunization: a look at GAVI. Bull WHO 82(9): 697–702PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2005

Authors and Affiliations

  • Philippe P.A. Beutels
    • 1
    • 2
  1. 1.Centre for the Evaluation of Vaccination, Department of Epidemiology and Community MedicineUniversity of AntwerpAntwerpenBelgium
  2. 2.National Centre for Immunisation Research Royal Alexandra Hospital for ChildrenUniversity of SydneyAustralia

Personalised recommendations